Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort 1A: preventive salpingo-oophorectomy with hormone replacement therapy | Healthy carriers who decide undergo preventive surgery and opt to have hormone replacement therapy | ||
| Cohort 1B: preventive salpingo-oophorectomy without hormone replacement therapy | Healthy carriers who decide undergo preventive surgery and reject hormone replacement therapy | ||
| Cohort 2: without preventive salpingo-oophorectomy | Healthy carriers who decide not to proceed to preventive surgery |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| To compare the scale MenCav of quality of life in premenopausal carriers opting and rejecting hormone replacement therapy post salpingo-oophorectomy | Questionnaire to measure quality of life in post-menopausal women (the Mencav questionnaire). This questionnaire consists of questions with 5 possible answers, answer 1 is the worst result and question 5 is the best result, so low scores mean worse results and high scores better results. | 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| To compare the impact of hormone replacement therapy on number and description of cardiovascular events | To describe cardiovascular risk we used changes in the weight of patients. Weight in kilograms, height in meters and weight and height will be combined to report BMI in kg/m^2. | 5 years |
| To compare the impact of hormone replacement therapy on number and description of cardiovascular events |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Women identified and followed at the Hospital de la Santa Creu i Sant Pau.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Teresa Ramon y Cajal, MD PhD | Contact | + 34 93 556 56 38 | 5634 | tramon@santpau.cat |
| Nuria Calvo, MD | Contact | + 34 93 556 56 38 | ncalvo@santpau.cat |
| Name | Affiliation | Role |
|---|---|---|
| Teresa Ramon y Cajal, MD PhD | Hospital Santa Cruz y San Pablo | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital de la Santa Creu i Sant Pau | Recruiting | Barcelona | 08041 | Spain |
Not provided
| ID | Term |
|---|---|
| D061325 | Hereditary Breast and Ovarian Cancer Syndrome |
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D010051 | Ovarian Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
To describe cardiovascular risk we used changes in blood pressure (mmHg) |
| 5 years |
| To compare the impact of hormone replacement therapy on number and description of cardiovascular events | To describe cardiovascular risk we used changes in lipids levels (cholesterol, triglycerides, HDL, LDL and VLDL) | 5 years |
| To compare the impact of hormone replacement therapy on number and description of cardiovascular events | To describe cardiovascular risk we used eventual cardiovascular adverse events | 5 years |
| To compare the impact of hormone replacement therapy on number and description of bone loss related events in premenopausal carriers after salpingo-oophorectomy we will perform bone densitometry | By performing bone densitometry we will be able to quantify the number of participants with adverse events related to bone loss (osteoporosis or osteopenia) | 5 years |
| Comparison of overall cancer survival between women deciding risk-reducing surgery and those rejecting it. | We will analyze and compare the mean of overall survival of women undergoing for risk-reducing surgery and those rejecting it | 5 years |
| Comparison of mean of breast cancer specific survival between women deciding gynecological surgery and those rejecting surgery. | We will analyze and compare the mean of breast cancer specific survival in women undergoing surgery and those rejecting it. | 5 years |
| Comparison of gynecologic cancer survival between women deciding preventive surgery and those rejecting it. | We will analyze and compare the mean of gynecologic cancer survival of women undergoing surgery and those rejecting it. | 5 years |
| D004701 |
| Endocrine Gland Neoplasms |
| D009386 | Neoplastic Syndromes, Hereditary |
| D010049 | Ovarian Diseases |
| D000291 | Adnexal Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D005833 | Genital Neoplasms, Female |
| D014565 | Urogenital Neoplasms |
| D000091662 | Genital Diseases |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D004700 | Endocrine System Diseases |
| D006058 | Gonadal Disorders |